Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Dec. 31, 2014 |
Dec. 31, 2013 |
|
| Operating expenses: | ||||||
| Research and development | $ 677,151 | $ 1,025,442 | $ 1,767,942 | $ 2,425,404 | $ 2,861,231 | $ 2,737,688 |
| Clinical and regulatory | 3,718,902 | 1,258,566 | 9,261,529 | 3,218,137 | 5,348,091 | 1,397,157 |
| General and administrative | 947,392 | 832,101 | 3,150,394 | 2,844,883 | 3,977,605 | 2,429,796 |
| Total operating expenses | 5,343,445 | 3,116,109 | 14,179,865 | 8,488,424 | 12,186,927 | 6,564,641 |
| Loss from operations | (5,343,445) | (3,116,109) | (14,179,865) | (8,488,424) | (12,186,927) | (6,564,641) |
| Interest income | 40,570 | 10,068 | ||||
| Interest income | 20,121 | 9,740 | 49,970 | 27,261 | ||
| Other income (expense) | 4,449 | (12,762) | 29,909 | (39,291) | (23,500) | 23,828 |
| Interest expense | (108,834) | (8,138) | (257,339) | (8,138) | (73,354) | (79,119) |
| Total non-operating (expenses) income | (84,264) | (11,160) | (177,460) | (20,168) | (56,284) | (45,223) |
| Net loss | (5,427,709) | (3,127,269) | (14,357,325) | (8,508,592) | (12,243,211) | (6,609,864) |
| Net loss - non-controlling interest | (242,244) | (126,865) | (549,190) | (330,675) | $ (454,394) | (198,516) |
| Beneficial conversion charge | (2,300,000) | |||||
| Preferred stock dividend | (361,668) | |||||
| Net loss attributable to Heat Biologics, Inc. | $ (5,185,465) | $ (3,000,404) | $ (13,808,135) | $ (8,177,917) | $ (11,788,817) | $ (9,073,016) |
| Net loss per share attributable to Heat Biologics, Inc.-basic and diluted | $ (0.62) | $ (0.46) | $ (1.75) | $ (1.27) | $ (1.83) | $ (2.42) |
| Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted | 8,408,376 | 6,469,272 | 7,880,637 | 6,445,129 | 6,454,866 | 3,747,357 |
| Net loss | $ (5,427,709) | $ (3,127,269) | $ (14,357,325) | $ (8,508,592) | $ (12,243,211) | $ (6,609,864) |
| Other comprehensive loss: | ||||||
| Unrealized loss on foreign currency translation | (27,244) | (64,238) | ||||
| Total comprehensive loss | (5,454,953) | $ (3,127,269) | (14,421,563) | $ (8,508,592) | ||
| Comprehensive loss attributable to non-controlling interest | (242,244) | (126,865) | (549,190) | (330,675) | ||
| Comprehensive loss - Heat Biologics, Inc. | $ (5,212,709) | $ (3,000,404) | $ (13,872,373) | $ (8,177,917) | ||